Next Article in Journal
Sustainability-Based Flood Hazard Mapping of the Swannanoa River Watershed
Next Article in Special Issue
Risk Measurement and Risk Modelling Using Applications of Vine Copulas
Previous Article in Journal
Analysis of Environmental Accounting and Reporting Practices of Listed Banking Companies in Bangladesh
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Sustainability 2017, 9(10), 1732;

Adoption of Falsified Medical Products in a Low-Income Country: Empirical Evidence for Suriname

Econometric Institute, Erasmus School of Economics, 3062PA Rotterdam, The Netherlands
Department of Economics, Anton de Kom University, Leysweg 86, P.O. Box 9212, Paramaribo, Suriname
Author to whom correspondence should be addressed.
Received: 10 August 2017 / Revised: 13 September 2017 / Accepted: 19 September 2017 / Published: 26 September 2017
(This article belongs to the Special Issue Risk Measures with Applications in Finance and Economics)
Full-Text   |   PDF [1308 KB, uploaded 26 September 2017]   |  


Based on detailed shipping figures for Suriname’s main harbour in Paramaribo, we estimate the total shipments (in kilograms) of original and falsified medical products for 1996–2008 across five product categories. Using various time series techniques and diffusion models, we document that total cumulative shipments of falsified products make about 40% of total shipments. We observe that there are apparently two distinct sets of consumers for original and for falsified products. Subsequently, we survey more than 300 citizens of Suriname from various demographics and ask questions about their potential adoption of falsified medicines. We find that income, age, and family size have no correlation, while the way people are insured does. Hence, the two sets of consumers can roughly be identified and clear-cut policy suggestions are presented. “The World Health Organization (WHO) estimates that up to 1% of medicines available in the developed world is likely to be counterfeited. This figure rises to 10% globally, although in some developing countries they estimate one third of medicines are counterfeit” (Various internet sites consulted January 2010 and the best estimate we have). View Full-Text
Keywords: falsified products; medication; health risk; low-income country falsified products; medication; health risk; low-income country

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Franses, P.H.; Lede, M. Adoption of Falsified Medical Products in a Low-Income Country: Empirical Evidence for Suriname. Sustainability 2017, 9, 1732.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Sustainability EISSN 2071-1050 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top